Real Clinics. Real Patients. Real Oncology.

Clinical Trials

CHAMP Trial Signals Activity for Chemoimmunotherapy in Aggressive Variant and Neuroendocrine Prostate Cancer

July 1, 2026
Listen to this
article

An Unmet Need in High-Risk Prostate Cancer

Neuroendocrine prostate cancer (NEPC) and aggressive variant prostate cancer (AVPC) are uncommon, clinically challenging phenotypes associated with poor outcomes. Platinum doublet chemotherapy is a standard treatment approach, but responses are often brief. The phase 2 CHAMP trial evaluated whether adding dual immune checkpoint blockade with nivolumab and ipilimumab to cabazitaxel plus carboplatin could improve disease control in this high-risk population.

A Multicenter, Prospective Treatment Strategy

CHAMP was a 2-stage, single-arm, prospective multicenter study. Eligible patients had metastatic NEPC or AVPC defined by histologic, clinical, or molecular features. Previous treatment with an androgen receptor pathway inhibitor (ARPI) was permitted, as were prior docetaxel and 1 previous platinum-containing regimen.

During combination therapy, patients received cabazitaxel, carboplatin, and nivolumab every 3 weeks plus ipilimumab every 6 weeks, with ongoing androgen-deprivation therapy. Chemotherapy was administered for up to 10 cycles and could be stopped earlier for response or toxicity. Patients without progression or unacceptable toxicity could continue maintenance nivolumab and ipilimumab. The primary end point was 6-month immune-modified radiographic progression-free survival (rPFS) by iRECIST/PCWG3 criteria.

Activity Exceeded the Historical Benchmark

The safety population included 40 patients, and 38 were evaluable for efficacy. Median age was 65 years. AVPC accounted for 70% of cases and NEPC for 30%. Visceral metastases were present in 73% of patients, including liver metastases in 58% and lung metastases in 33%. Most patients had received a prior ARPI, and 78% had received prior chemotherapy.

At a median follow-up of 18 months, the 6-month immune-modified rPFS rate was 74%, compared with the prespecified historical control of 55% (P=.013). Median immune-modified rPFS was 12 months (95% CI, 9.1-14). By conventional RECIST assessment, median rPFS was 6.1 months (95% CI, 4.3-8-6). Median overall survival was 12 months (95% CI, 11-17), and the investigator-assessed objective response rate was 37% (95% CI, 22-54), with a median response duration of 9.3 months. Two patients remained free of disease and off therapy at 30 months.

Toxicity Requires Careful Patient Selection and Monitoring

The regimen was feasible but clinically demanding. Grade 3 treatment-related adverse events occurred in 50% of patients, and grade 4 events occurred in 16%. Common treatment-related events included anemia, nausea, fatigue, diarrhea, decreased platelet count, hypomagnesemia, dyspnea, anorexia, paresthesia, rash, and colitis. The most concerning toxicities included febrile neutropenia, sepsis, colitis, endocrinopathies, and other immune-related adverse events. No treatment-related deaths were reported.

Takeaways

Dual PD-1/CTLA4 immune checkpoint blockade with platinum doublet chemotherapy is effective in patients with AVPC/NEPC, resulting in greater efficacy than expected with historic platinum chemotherapy alone, and with acceptable toxicity given disease risk. Randomized controlled trials are needed to define the overall risk-benefit profile, confirm whether chemoimmunotherapy delays progression or improves survival, and clarify effects on quality of life.

Sources

Armstrong AJ, Howard L, Harrison MR, et al. Phase 2 multicenter trial of chemoimmunotherapy for patients with neuroendocrine or aggressive variant metastatic prostate cancer (CHAMP). Presented at: 2026 American Society of Clinical Oncology Annual Meeting. Abstract 5016. Slide presentation.

Armstrong AJ, Howard L, Harrison MR, et al. Phase 2 multicenter trial of chemoimmunotherapy for patients with neuroendocrine or aggressive variant metastatic prostate cancer (CHAMP). J Clin Oncol. 2026;44(suppl):5016. doi:10.1200/JCO.2026.44.16_suppl.5016

Share this article

Oncology is evolving.
  Stay current.  

Weekly breakthroughs, expert insights, and clinical updates —delivered to your inbox.

Further Reading

What are you
looking for?

POPULAR SEARCHES